Imunon (IMNN) CFO receives grant of 9,050 stock options at $3.95

Rhea-AI Filing Summary

Imunon, Inc. reported an insider equity award for its CFO, Kimberly Bragg. On January 2, 2026, she received a stock option grant covering 9,050 shares of Imunon common stock at an exercise price of $3.95 per share, which the filing notes is the closing share price on the grant date. The options vest over time: one-half on the grant date, one-quarter on the first anniversary, and one-quarter on the second anniversary of the grant date. Following this grant, Bragg beneficially owns 9,050 derivative securities directly in the form of these options.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bragg Kimberly

(Last) (First) (Middle)

C/O IMUNON, INC.

997 LENOX DRIVE, SUITE 100

(Street)

LAWRENCEVILLE NJ 08648

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Imunon, Inc. [ IMNN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.95(1)	01/02/2026		A		9,050		01/02/2026(2)	01/02/2036	Common Stock	9,050	$0	9,050	D

Explanation of Responses:

1. Represents the closing price of Imunon, Inc. Common Stock on the date of the grant

2. The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant.

	/s/ Kimberly Graper	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Imunon (IMNN) disclose in this Form 4?

The filing discloses that Imunon, Inc. granted its CFO, Kimberly Bragg, stock options for 9,050 shares of common stock on January 2, 2026.

Who is the insider involved in the latest Imunon (IMNN) Form 4 filing?

The insider is Kimberly Bragg, who serves as CFO of Imunon, Inc. and is the sole reporting person on the Form 4.

How many Imunon stock options were granted to the CFO and at what price?

Kimberly Bragg was granted 9,050 stock options, each with an exercise price of $3.95 per share, which equals the closing price on the grant date.

What is the vesting schedule for the Imunon (IMNN) CFO’s stock options?

The options vest as follows: 1/2 on the grant date, 1/4 on the one-year anniversary, and 1/4 on the two-year anniversary of the grant date.

Does the Imunon CFO hold these stock options directly or indirectly?

The Form 4 indicates the 9,050 stock options are held with direct ownership by Kimberly Bragg.

How many derivative securities does the Imunon CFO own after this Form 4 transaction?

After the reported grant, Kimberly Bragg beneficially owns 9,050 derivative securities, all represented by these stock options.